A two-part, phase I study of single and repeat doses of dipraglurant (ADX 48621) in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2009
At a glance
- Drugs Dipraglurant (Primary)
- Indications Anxiety disorders; Depressive disorders; Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Addex Therapeutics
- 28 Jan 2009 Status changed from recruiting to completed, as reported in Addex Pharmaceuticals media release.
- 28 Oct 2008 Addex Pharmaceuticals has announced that the first part of this study has been completed.
- 28 Oct 2008 Status changed from planning to recruiting.